GlassScriptPhysician profile
Domonick Gordon
NPI 1245804574
$443.13
in general payments reported to CMS, 2019-2025
9 companies · $443 in 2025
The $443 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $365 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $365.14 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $91.10 | 2025 | Enhertu, Lynparza, Calquence |
| Incyte Corporation | $81.70 | 2025 | Jakafi |
| Daiichi Sankyo INC. | $77.99 | 2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $47.64 | 2025 | Ninlaro |
| Alexion Pharmaceuticals, INC. | $42.43 | 2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $29.81 | 2025 | |
| Jazz Pharmaceuticals INC. | $28.07 | 2025 | |
| Genzyme Corporation | $23.16 | 2025 | |
| Deciphera Pharmaceuticals INC. | $21.23 | 2025 | Romvimza, Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Domonick Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.